Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib open-label extension in pediatric juvenile idiopathic arthritis
2025-523239-21-00Phase 3Authorised
- Sponsor
- Alfasigma
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of filgotinib in juvenile idiopathic arthritis (JIA), sponsored by Alfasigma. Primary endpoint: Treatment-emergent adverse events. Planned start Apr 2026; status: authorised.
02
Drugs
filgotinib
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2025-523239-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523239-21-00.